Thanks largely to wide media coverage the past several years (including a physician’s report on the life-altering effects of THC and CBD cannabis oil THC on a child suffering from a severe seizure disorder), cannabis has been cast back in the spotlight for its powerful anti-seizure properties.
Cannabis Oil THC Research
With a lot of buzz going on, it’s surprising to know that personal accounts on cannabis use for treating seizures have been around for hundreds of years with documentation dating as early as 1881. But research on its effects against epilepsy and seizures is still in its infancy stages.
With many families in the U.S. who want access to CBD to treat their children, the need for research studies is becoming urgent. Currently, there’s a huge need for resolving adult and pediatric treatment-resistant epilepsy syndromes in the country (which affects more than 700,000 Americans). Some of the biggest needs are found in children suffering from severe epilepsy syndromes, where seizures are persistent despite multiple anti-epileptic drug efforts.
Previous Data Results
A U.S.-based non-profit research firm of herbal medicine responded to this need by unveiling scientific reviews of current cannabis oil the research, seizures, and epilepsy to the public.
Based on published evidence, reviews made by multiple authors led to several conclusions on the possible benefits of cannabis on seizures and epilepsy. These include:
- A general agreement of cannabis offering anticonvulsant properties.
- Human evidence indicating reduced seizure severity and frequency including improved behavior and physical performance due to cannabis intake.
- High variability on varying factors
- CBD offering dependable anticonvulsant effects in children suffering from antiepileptic drugs.
- CBD is generally tolerated by children without triggering motor and/or neurotoxic effects.
- CBDV preliminary results (a biological derivative of the CBD), indicate that it may be a little more effective than CBD although with limited availability.
Scientists say that while such results are encouraging, it’s still too early to tell. They stress on the need for repetitive dosages, longer studies in different animal disease models, and controlled clinical trials to determine its safety and effectiveness in the long term.
Next Research Steps
At this point, attempts by medical researchers to research cannabis in the United States have been delayed as a result of marijuana being listed as a Scheduled I substance by the Drug Enforcement Agency (DEA). However, a majority of the country’s medical community believe it to be false and are pushing hard for research and medical entry to cannabis.
To improve research, the AAP (American Academy of Pediatrics) recommended the DEA to re-assign marijuana as a Schedule II substance. Such downgrade would let the DFA (Drug Enforcement Agency) be involved in pediatric research studies. This is essential for the AAP for offering a standardization process.
As a matter of fact, the FDA recently approved the Investigational New Drug Studies of cannabis oil thc as an ant-epileptic drug through a pharmaceutical firm.